info@epichembio.eu + 34 986 812 316

Oppermann Group. Epigenetic Mechanisms in Musculoskeletal Disease

udo.oppermann@sgc.ox.ac.uk
www.ndorms.ox.ac.uk/team/udo-oppermann
Address
Botnar Research Centre, University of Oxford, OX3 7LD, UK
United Kingdom
Keywords

histone demethylase, Jumonji enzymes, epigenetic screening, epigenetic inhibitor, primary cell culture

Models

myeloma, sarcoma cell culture, multiple myeloma, mesenchymal stem cells, various inflammatory cell types

Techniques

assay development, primary cell culture, inhibitor characterisation, mesenchymal stem cell, bone oncology, Cytof, CHIPseq, RNAseq, ATACseq

Collaborations outside COST

Nick Athanasou (Oxford), Nick LaThangue (Oxford), Chris Schofield/Akane Kawamura (Oxford), Paul Brennan/Chas Bountra (SGC Oxford); Jun Qi (Dana Farber), Roland Schuele (Freiburg); Hinrich Gronemeyer (Strasbourg); Tamer Onder (Istanbul);

Short description of ongoing research projects

The use of chemical biology to understand human biology is a major focus of the Oppermann group and is currently applied to the field of epigenetic mechanisms in stem cell biology, as well as chronic inflammatory and metabolic diseases.

Publications
  1. Nowak RP, Tumber A, Johansson C, Che KH, Brennan P, Owen D, Oppermann U. Advances and challenges in understanding histone demethylase biology. Curr Opin Chem Biol. 2016 Aug;33:151-9. doi: 10.1016/j.cbpa.2016.06.021. Epub 2016 Jun 29. Review. PubMed PMID: 27371875.
  2. Johansson C, Velupillai S, Tumber A, Szykowska A, Hookway ES, Nowak RP, Strain-Damerell C, Gileadi C, Philpott M, Burgess-Brown N, Wu N, Kopec J, Nuzzi A, Steuber H, Egner U, Badock V, Munro S, LaThangue NB, Westaway S, Brown J, Athanasou N, Prinjha R, Brennan PE, Oppermann U. Structural analysis of human KDM5B guides histone demethylase inhibitor development. Nat Chem Biol. 2016 Jul;12(7):539-45. doi: 10.1038/nchembio.2087. Epub 2016 May 23. PubMed PMID: 27214403.
  3. Hillringhaus L, Yue WW, Rose NR, Ng SS, Gileadi C, Loenarz C, Bello SH, Bray JE, Schofield CJ, Oppermann U. Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family. J Biol Chem. 2011 Dec 2;286(48):41616-25. doi: 10.1074/jbc.M111.283689. Epub 2011 Sep 13. PubMed PMID: 21914792; PubMed Central PMCID: PMC3308871.
  4. Johansson C, Tumber A, Che K, Cain P, Nowak R, Gileadi C, Oppermann U. The roles of Jumonji-type oxygenases in human disease. Epigenomics. 2014 Feb;6(1):89-120. doi: 10.2217/epi.13.79. Review. PubMed PMID: 24579949; PubMed Central PMCID: PMC4233403.
  5. Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, Eberhard D, Hutchinson S, Jones E, Katso R, Leveridge M, Mander PK, Mosley J, Ramirez-Molina C, Rowland P, Schofield CJ, Sheppard RJ, Smith JE, Swales C, Tanner R, Thomas P, Tumber A, Drewes G, Oppermann U, Patel DJ, Lee K, Wilson DM. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012 Aug 16;488(7411):404-8. doi: 10.1038/nature11262. PubMed PMID: 22842901; PubMed Central PMCID: PMC4691848.
Other activities of potential interest to others


Cost UE